Getein Biotech Croissance FCF

Que fait Getein Biotech ? Getein Biotech Inc, listed on the Shanghai Stock Exchange under ticker 603387.SS, is a biotechnology company headquartered in Nanjing, China. The company went public on July 17, 2017, and currently employs 2,508 full-time staff. Its primary business focuses on the medical health industry chain, with operations centered around in vitro diagnostic reagents and related instruments. The company produces a range of diagnostic reagents, including Point-of-care Testing (POCT) reagents, chemiluminescence reagents, biochemical reagents, blood cell reagents, and hemagglutination reagents. It also develops diagnostic instruments such as the immunoquantitative analyzer FIA 8000, immunoquantitative analyzer FIA 8600, fluorescence immunoquantitative analyzer Getein 1100, fluorescence immunoquantitative analyzer Getein 1180, automatic biochemical analyzer CM 400, automatic chemiluminescence analyzer MAGICL 6000, and the five classification blood cell analyzer BHA-5000. In addition to manufacturing, Getein Biotech offers testing and agency services. Its products are distributed both domestically within China and internationally. The company maintains a website at www.getein.com.cn for further information. As a biotechnology firm operating in the healthcare sector, Getein Biotech Inc is positioned within the broader health care industry, contributing to diagnostic solutions for medical professionals and institutions. The company's focus on in vitro diagnostics aligns with its role in supporting healthcare systems through advanced testing technologies and equipment. Getein Biotech est l'une des entreprises les plus populaires sur Eulerpool.